BMB-201

BMB-201
Clinical data
Other namesBMB201; BMB-A39a prodrug
Drug classNon-hallucinogenic serotonin 5-HT2A and 5-HT2C receptor partial agonist[1][2][3][4]

BMB-201 is a serotonin 5-HT2A and 5-HT2C receptor agonist described as a non-hallucinogenic psychoplastogen which is under development for the treatment of depression, anxiety, pain, and other indications.[1][2][3][4]

The drug is a prodrug of another compound called BMB-A39a.[3][4] It acts as a partial agonist of the serotonin 5-HT2A and 5-HT2C receptors.[1][2][3][4] BMB-A39a is less efficacious in activating Gq signaling at the serotonin 5-HT2A and 5-HT2C receptors compared to psilocin (EmaxTooltip Maximal efficacy = 68% vs. 82% at 5-HT2A and 79% vs. 95% at 5-HT2C for BMB-201 and psilocin, respectively).[4] The EC50Tooltip half-maximal effective concentration value of BMB-A39a in activating the serotonin 5-HT2C receptor is around 10-fold higher than for activating the 5-HT2A receptor (EC50 = 6.7 nM and 71.2 nM, respectively).[4] In addition to the serotonin 5-HT2A and 5-HT2C receptors, BMB-A39a is a potent partial agonist of the serotonin 5-HT1F and 5-HT6 receptors.[3] Conversely, BMB-A39a shows minimal or negligible activity in activating the serotonin 5-HT2B receptor (Emax < 20%) and does not activate other serotonin receptors.[3][4]

BMB-201 is said to have minimal or absent psychedelic effects due to its reduced serotonin 5-HT2A receptor intrinsic activity but to potently induce neuroplasticity.[3][4] It has been reported to show effectiveness in animal models of depression, anxiety, pain, and substance use disorder.[3][5][4]

BMB-201 is under development by Bright Minds Biosciences.[1][2] As of October 2024, its highest developmental phase is preclinical research.[1][2] The chemical structure of BMB-201 does not yet appear to have been disclosed.[1][2]

See also

References

  1. 1 2 3 4 5 6 "Delving into the Latest Updates on BMB-201 with Synapse". Synapse. 29 October 2024. Retrieved 30 October 2024.
  2. 1 2 3 4 5 6 "BMB-201 Drug Profile". Ozmosi. Retrieved 30 October 2024.
  3. 1 2 3 4 5 6 7 8 Vasilkevich A, Duan J, Lovera A, McCorvy J, Pedersen JT (October 2024). Novel 5-HT2A/2C mixed and partial agonist and its efficacy in preclinical pain models (PDF). Society for Neuroscience 2024 Annual Meeting, Chicago, October 5-9.
  4. 1 2 3 4 5 6 7 8 9 "Bright Minds Investor Deck" (PDF). Bright Minds Biosciences Inc. September 2024.
  5. ↑ "Bright Minds Biosciences proprietary compound, BMB-201, 5-HT2C/2A mixed agonist, demonstrated similar efficacy to morphine in preclinical pain models". BioSpace. 17 October 2024. Retrieved 30 October 2024.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.